Zsolt Pápai

Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer

John R. Eckardt, Joachim von Pawel, Jean-Louis Pujol et al. · Journal of Clinical Oncology · 2007 · 384 citations

Medicine, Oncology, Pharmacology +13

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial

Élisabeth Quoix, Rodryg Ramlau, Virginie Westeel et al. · The Lancet Oncology · 2011 · 265 citations

Medicine, Immunology, Oncology +15

Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial

Giorgio V. Scagliotti, Maciej Krzakowski, Aleksandra Szczęsna et al. · Journal of Clinical Oncology · 2012 · 212 citations

Medicine, Oncology, Pharmacology +17

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial

Élisabeth Quoix, H. Léna, György Losonczy et al. · The Lancet Oncology · 2015 · 207 citations

Medicine, Immunology, Oncology +13

Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin As Treatment for Chemotherapy-Naive Patients With Extensive-Disease Small-Cell Lung Cancer

John R. Eckardt, Joachim von Pawel, Zsolt Pápai et al. · Journal of Clinical Oncology · 2006 · 147 citations · Full text

Medicine, Oncology, Pharmacology +10